MA51132A - Sel de fumarate de l'urée (r)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phényl)-2,2,2-trifluoroéthyl)-1-méthyl-1-(1-méthylpipéridin-4-yl), procédés de préparation et utilisations de celui-ci - Google Patents

Sel de fumarate de l'urée (r)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phényl)-2,2,2-trifluoroéthyl)-1-méthyl-1-(1-méthylpipéridin-4-yl), procédés de préparation et utilisations de celui-ci

Info

Publication number
MA51132A
MA51132A MA051132A MA51132A MA51132A MA 51132 A MA51132 A MA 51132A MA 051132 A MA051132 A MA 051132A MA 51132 A MA51132 A MA 51132A MA 51132 A MA51132 A MA 51132A
Authority
MA
Morocco
Prior art keywords
methylpiperidin
pyrazin
trifluoroethyl
dichloro
phenyl
Prior art date
Application number
MA051132A
Other languages
English (en)
Inventor
Rubio Silvina Garcia
Claudio Giuliano
Angelo Guainazzi
Mauro Perseghini
Claudio Pietra
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of MA51132A publication Critical patent/MA51132A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA051132A 2017-12-11 2018-12-07 Sel de fumarate de l'urée (r)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phényl)-2,2,2-trifluoroéthyl)-1-méthyl-1-(1-méthylpipéridin-4-yl), procédés de préparation et utilisations de celui-ci MA51132A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762597236P 2017-12-11 2017-12-11

Publications (1)

Publication Number Publication Date
MA51132A true MA51132A (fr) 2020-10-21

Family

ID=64901108

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051132A MA51132A (fr) 2017-12-11 2018-12-07 Sel de fumarate de l'urée (r)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phényl)-2,2,2-trifluoroéthyl)-1-méthyl-1-(1-méthylpipéridin-4-yl), procédés de préparation et utilisations de celui-ci

Country Status (19)

Country Link
US (2) US11299472B2 (fr)
EP (1) EP3724176B1 (fr)
JP (1) JP7171728B2 (fr)
KR (1) KR20200097762A (fr)
CN (1) CN111683934B (fr)
AU (1) AU2018385438B2 (fr)
BR (1) BR112020010803A2 (fr)
CL (1) CL2020001553A1 (fr)
DK (1) DK3724176T3 (fr)
EA (1) EA202091402A1 (fr)
ES (1) ES2910030T3 (fr)
HU (1) HUE058247T2 (fr)
IL (1) IL275153B2 (fr)
LT (1) LT3724176T (fr)
MA (1) MA51132A (fr)
MX (1) MX2020006026A (fr)
SI (1) SI3724176T1 (fr)
WO (1) WO2019118298A1 (fr)
ZA (1) ZA202002957B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020011727A2 (pt) 2017-12-11 2020-11-17 Technische Universität München ligantes de psma para imageamento e endorradioterapia
CN111303192A (zh) * 2020-03-26 2020-06-19 西安瑞联新材料股份有限公司 一种3-氯-2-萘硼酸的工业化生产方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005048916A2 (fr) 2003-11-20 2005-06-02 Biovitrum Ab Nouvelles carbolines-beta en tant qu'antagonistes de recepteur de secretagogue d'hormone de croissance
WO2011060397A1 (fr) 2009-11-16 2011-05-19 Schering Corporation Amino heterocycles substitues utilises comme antagonistes du vih
WO2012113103A1 (fr) 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Urées asymétriques et leurs utilisations médicales
TWI703130B (zh) * 2014-03-07 2020-09-01 瑞士商赫爾辛保健股份有限公司 對位取代的不對稱脲及其醫療用途

Also Published As

Publication number Publication date
HUE058247T2 (hu) 2022-07-28
ZA202002957B (en) 2025-04-30
SI3724176T1 (sl) 2022-04-29
IL275153A (en) 2020-07-30
AU2018385438A8 (en) 2020-06-04
AU2018385438A1 (en) 2020-05-28
WO2019118298A1 (fr) 2019-06-20
US11884646B2 (en) 2024-01-30
LT3724176T (lt) 2022-04-25
JP7171728B2 (ja) 2022-11-15
ES2910030T3 (es) 2022-05-11
JP2021505633A (ja) 2021-02-18
IL275153B2 (en) 2024-12-01
AU2018385438B2 (en) 2022-12-15
EP3724176B1 (fr) 2022-01-26
CN111683934A (zh) 2020-09-18
US20220340541A1 (en) 2022-10-27
KR20200097762A (ko) 2020-08-19
DK3724176T3 (da) 2022-04-04
CN111683934B (zh) 2024-01-23
CA3083509A1 (fr) 2019-06-20
EP3724176A1 (fr) 2020-10-21
US11299472B2 (en) 2022-04-12
US20200299260A1 (en) 2020-09-24
CL2020001553A1 (es) 2020-11-06
MX2020006026A (es) 2020-08-17
IL275153B1 (en) 2024-08-01
BR112020010803A2 (pt) 2020-11-10
EA202091402A1 (ru) 2020-09-01

Similar Documents

Publication Publication Date Title
MA52781A (fr) Anticorps contre entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
MA53380A (fr) Systèmes d'injection, outils d'injection et procédés associés
MX2022004992A (es) Uso de compuestos de 3-isoxazolidinonas como herbicidas selectivos.
WO2018089261A3 (fr) Composés et méthodes de modulation de kinase de lymphocytes t inductible par l'interleukine 2
EP3787665A4 (fr) Systèmes, procédés et appareils d'électroporation
EP3484367A4 (fr) Prévention de l'encrassement biologique de capteurs portatf, procédés d'utilisation et d'étalonnage.
MX2020001302A (es) Procesos para preparar compuestos de pirrolidina.
EP3434676A4 (fr) Inhibiteur de cdk pyrrolopyrimidine substituée, composition pharmaceutique le comprenant et son utilisation
EP3781563A4 (fr) Inhibiteurs d'hpk1, procédé de préparation et utilisation associés
WO2017156495A8 (fr) Composés et procédés pour moduler la tyrosine kinase de bruton
MA52492A (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
EP3748995A4 (fr) Procédé de transfert, procédé d'échange d'informations, dispositif, et support de stockage lisible par ordinateur
WO2017177222A8 (fr) Système et procédé de recherche et de mise en correspondance de contenu sur des réseaux sociaux pertinent pour un individu
CL2021000373S1 (es) Contenedor. (divisional solicitud 202000878)
BRPI0507794A (pt) métodos de modular a atividade de il-23, reagentes relacionados
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
EP3807348A4 (fr) Gels cellulosiques, films et composites comprenant les gels, et procédés de formation de ceux-ci
DK3345900T3 (da) 2,4-bis-(nitrogenholdig gruppe)-substitueret pyrimidinforbindelse samt fremgangsmåde til fremstilling og anvendelse deraf
DK3752490T3 (da) Herbicide 3-azaspiro[5.5]undecan-8,10-dionforbindelser
WO2018064191A8 (fr) Procédé de traitement du carcinome urothélial et d'autres malignités génito-urinaires à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy)phényl)-n'-(4-fluorophényl)cyclopropane -1,1-dicarboxamide
IL282254A (en) Compounds, compositions, and methods for modulating cdk9 activity
EP3911207A4 (fr) Ensembles récipients à usage unique pour préparation d'aliments, systèmes et procédés
DK3833434T3 (da) Forbindelser, der er nyttige ved modulering af farnesoid-x-receptoren, samt fremgangsmåder til fremstilling og anvendelse heraf
EP4050721A4 (fr) Séparateur pour dispositif électrochimique, et dispositif électrochimique comprenant celui-ci
IL292266A (en) Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benz yl)amino)isoindoline-1,3-dione